Iain Thomas

Iain is Head of Technology Development and Licensing (TDL) at Cambridge Enterprise and manages a team of 35+.  The TDL team, work with researchers to commercialise their work from all areas of Cambridge’s research base.  The team have spun-out Nybolt, Xampla, Impossible Materials, Mission Therapeutics, XO1 Therapeutics (sold to Janssen), Phoremost, Predictimmune, DIOSynVax, Storm Therapeutics, Gyroscope Therapeutics (sold to Novartis), NoBACZ, Zomp, Morphogenix, Apcintex and Z‑Factor.

Iain founded Apollo Therapeutics which raised £40m (2016), $145m (2021), $250m (2023) with colleagues from Imperial College and UCL.  He developed Ceres-Agritech based on Apollo Therapeutics to do the same in agritech.